Alnylam Pharmaceuticals, Inc. (ALNY) — Stock Score Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has a MoatMap StockRank of 33/100 based on Quality (73/100), Value (13/100), and Momentum (35/100) factor scores. The current signal is SELL. Alnylam Pharmaceuticals is a pioneer in RNAi therapeutics. While it is a high-quality biotech company, it is a drug developer rather than a CDMO, meaning it does not directly benefit from our CDMO Pricing Power Cycle theme and faces high binary clinical trial risks.

Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on developing and commercializing innovative RNA interference (RNAi) therapeutics for rare genetic diseases. The company is a pioneer and market leader in the RNAi field, leveraging its proprietary technology platforms, extensive intellectual property, and a growing portfolio of approved drugs. Alnylam's competitive advantage lies in its ability to translate groundbreaking science into transformative medicines for patients with significant unmet needs.

Key Financial Metrics

Price$297.69
Market Cap$40.7B
P/E (TTM)76.29
P/E (Forward)21.85
Price/Book37.68
Return on Equity90.4%
Return on Invested Capital16.5%
Debt/Equity276.20
Gross Margin80.8%
Operating Margin23.0%
Revenue Growth96.4%
Free Cash Flow$205M

Alnylam Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Alnylam Pharmaceuticals, Inc.’s (ALNY) StockRank?
MoatMap’s StockRank for Alnylam Pharmaceuticals, Inc. (ALNY) is 33/100, with a Sell signal. It is a composite of Quality (73), Value (13), and Momentum (35) factor ranks across MoatMap’s 19,000+ stock universe.
Does Alnylam Pharmaceuticals, Inc. have an economic moat?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Quality factor score of 73/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Alnylam Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Alnylam Pharmaceuticals, Inc. (ALNY) is Sell, based on a StockRank of 33/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Alnylam Pharmaceuticals, Inc. in?
Alnylam Pharmaceuticals, Inc. (ALNY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksALNY deep dive reportAI ChampionsHow we score stocksSense-check another stock